Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer (NSCLC) that confer sensitivity to the ALK inhibitors crizotinib and ceritinib. To determine the outcome of sequential treatment with crizotinb and ceritinib, we retrospectively e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Gainor, Justin F., Tan, Daniel S.W., De Pas, Tomasso, Solomon, Benjamin J., Ahmad, Aziah, Lazzari, Chiara, de Marinis, Filippo, Spitaleri, Gianluca, Schultz, Katherine, Friboulet, Luc, Yeap, Beow Y., Engleman, Jeffrey A., Shaw, Alice T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4470734/
https://ncbi.nlm.nih.gov/pubmed/25724526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados